Patent: 11,279,698
✉ Email this page to a colleague
Summary for Patent: 11,279,698
| Title: | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer |
| Abstract: | The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following: |
| Inventor(s): | Babich John W., Wilson Justin, Thiele Nikki, Kelly James, Ponnala Shashikanth |
| Assignee: | Cornell University |
| Application Number: | US16689856 |
| Patent Claims: | see list of patent claims |
Details for Patent 11,279,698
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Aytu Bioscience, Inc. | PROSTASCINT | capromab pendetide | Injection | 103608 | 28-Oct-96 | 11,279,698 | 2039-11-20 |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 7-May-01 | 11,279,698 | 2039-11-20 |
| Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | 14-Nov-14 | 11,279,698 | 2039-11-20 |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 12-Oct-04 | 11,279,698 | 2039-11-20 |
| Glaxosmithkline Llc | BENLYSTA | belimumab | For Injection | 125370 | 9-Mar-11 | 11,279,698 | 2039-11-20 |
| Seagen Inc. | ADCETRIS | brentuximab vedotin | For Injection | 125388 | 19-Aug-11 | 11,279,698 | 2039-11-20 |
| Sanofi-aventis U.s. Llc | ZALTRAP | ziv-aflibercept | Injection | 125418 | 3-Aug-12 | 11,279,698 | 2039-11-20 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
